PubRank

The Janus face of p21.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27857977)

Published in Mol Cell Oncol on July 29, 2016

Authors

Konstantinos Evangelou1, Panagiotis Galanos1, Vassilis G Gorgoulis2

Author Affiliations

1: Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens , Athens, Greece.
2: Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Faculty Institute for Cancer Sciences, Manchester Academic Health Sciences Center, University of Manchester, Manchester, UK; Biomedical Research Foundation, Academy of Athens, Athens, Greece.

Articles cited by this ↗

p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21

Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci (2003) 5.26

Translocations involving c-myc and c-myc function. Oncogene (2001) 3.21

p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol (1994) 2.41

Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. Nat Cell Biol (2016) 1.76

Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev (2007) 1.65

Regulation of ploidy and senescence by the AMPK-related kinase NUAK1. EMBO J (2009) 1.33

Myc degradation: dancing with ubiquitin ligases. Proc Natl Acad Sci U S A (2004) 1.31

D-type cyclin-binding regions of proliferating cell nuclear antigen. J Biol Chem (1994) 1.18

Aberrant regulation of FBW7 in cancer. Oncotarget (2014) 1.08